Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients

Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients

Ji Eun Park,1,* Mi Jeong Hong,2,3,* Shin Yup Lee,1,4 Jang Hyuck Lee,2,4 Jin Eun Choi,2,3 Hyo-Gyoung Kang,2,3 Sook Kyung Do,2,3 Ji Yun Jeong,5 Kyung Min Shin,6 Won Kee Lee,7 Sun Ha Choi,1 Yong Hoon Lee,1 Hye won Seo,1 Seung Soo Yoo,1 Jaehee Lee,1 Seung Ick Cha,1 Chang Ho Kim,1 Jae Yon...

Full description

Bibliographic Details
Main Authors: Park JE, Hong MJ, Lee SY, Lee JH, Choi JE, Kang HG, Do SK, Jeong JY, Shin KM, Lee WK, Choi SH, Lee YH, Seo HW, Yoo SS, Lee J, Cha SI, Kim CH, Park JY
Format: Article
Language:English
Published: Dove Medical Press 2021-10-01
Series:Pharmacogenomics and Personalized Medicine
Subjects:
lung adenocarcinoma
egfr-tki
clinical outcome
mirna binding site
polymorphism
Online Access:https://www.dovepress.com/nuclear-pore-glycoprotein-62-genetic-variant-rs9523-is-associated-with-peer-reviewed-fulltext-article-PGPM

Internet

https://www.dovepress.com/nuclear-pore-glycoprotein-62-genetic-variant-rs9523-is-associated-with-peer-reviewed-fulltext-article-PGPM

Similar Items